Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Goji Berries and Energy Expenditure

31. Januar 2017 aktualisiert von: Maastricht University Medical Center

The Effect of a Single Dose of Lycium Barbarum on Postprandial Energy Expenditure in Healthy Overweight Men

Effects of foods or food substances on energy expenditure are of particular interest, because of the increasing prevalence of obesity and its consequent metabolic diseases like type II diabetes and fatty liver disease, all risk factors for the development of cardiovascular diseases (CVDs). Recently, the Goji berry (Lycium Barbarum, wolfberry) was introduced into the Western diet. L. Barbarum originates from Asia, where it is used to improve the health of several organs. Although L. Barbarum is promoted as a super food with many beneficial effects, consistent scientific evidence for these effects is lacking. In one study, it was found that short-term intake of L. Barbarum polysaccharides - equal to 150 g of fresh berries - increased postprandial oxygen consumption. This indicates that L. Barbarum might exert beneficial effects on energy expenditure. Furthermore, long-term intervention trials have shown beneficial effects of L. Barbarum on lipid and glucose metabolism in mice and type II diabetic patients and on inflammatory status in healthy elderly. Altogether, L. Barbarum has the potential to be used as a functional food to increase metabolic health, but detailed information on the postprandial effects of L. Barbarum is missing. We therefore propose this double-blinded, randomized, placebo controlled intervention trial to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure substrate oxidation, metabolic flexibility, lipid and glucose metabolism and inflammatory markers.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Objectives:

The primary objective of this study is to investigate the effect of a single dose of L. Barbarum on postprandial energy expenditure. Secondary objectives are to investigate the effect of a single dose of L. Barbarum on postprandial lipid and carbohydrate oxidation and metabolic flexibility, on postprandial lipid and glucose metabolism and on inflammatory markers.

Study design:

This is a double blind, randomized, placebo-controlled intervention trial with two test days separated by a washout period of at least 1 week.

Study population:

The study population will consist of 20 apparently healthy overweight (BMI between 25 and 30 kg/m2) men aged 18-65 years.

Intervention:

All subjects will receive a mixed meal including 25 grams of dried L. Barbarum as the intervention product and a matched mixed meal without L. Barbarum as the placebo product. The meals will be matched for energy content and macronutrient composition.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

18

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Niederlande
    • Limburg
      • Maastricht, Limburg, Niederlande, 6229 ER
        • Maastricht University Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Männlich

Beschreibung

Inclusion Criteria:

  • Male gender
  • BMI between 25 and 30 kg/m2
  • Non-smoking
  • Normal fasting triacylglycerol levels (<2.2 mmol/L)
  • No hyperglycaemia or hypercholesterolemia (fasting glucose < 7.0 mmol/L and total cholesterol < 8.0 mmol/L)
  • Willing to comply to the study protocol during the study
  • Agreeing to be informed about medically relevant personal test-results

Exclusion Criteria:

  • Use of anticoagulant medication
  • Unstable body weight (weight gain or loss >3 kg in the past 3 months)
  • Indications of treatment according to the Standard for Cardiovascular Risk Management from the Dutch General Practitioners community
  • Any medical condition that might interfere with study measurements, judged by the principal investigator, including cardiovascular disease or events (e.g. acute myocardial infarction or cerebra-vascular accident), diabetes or hypercholesterolemia
  • Use of any kind of medication or medically prescribed diet, which can interfere with the study (judged by the principal investigator). The use of paracetamol is allowed
  • Use of oral antibiotics (with the exception of topical antibiotics) in 40 days or less prior to the start of the study
  • Use of food supplements or plant-sterol/stanol-enriched foods or supplements in the three weeks prior to the screening and/or during the study
  • Not willing to abstain from L. Barbarum consumption thee weeks before the start and during the trial
  • Severe medical conditions that might interfere with the study, such as epilepsy, asthma, chronic obstructive pulmonary disease and rheumatoid arthritis
  • Consumption of > 14 alcohol consumptions a week
  • Reported intense sporting activities > 10 hours a week
  • Abuse of drugs
  • Participation in any other biomedical trial one month prior to the screening visit
  • Having donated > 150 ml blood within 1 month prior to the screening visit, planning to donate blood during the study or within one month after finishing the study
  • Impossible or difficult to puncture as evidenced during the screening visit

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Lycium Barbarum mixed meal
Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
Nahrungsergänzungsmittel: Lycium Barbarum mixed meal
This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
Aktiver Komparator: Control mixed meal
Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
Nahrungsergänzungsmittel: Control mixed meal
This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline energy expenditure
Zeitfenster: Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake
Energy expenditure will be measured using indirect calorimetry (ventilated hood system). This system measures oxygen consumption (VO2) and carbon dioxide production (VCO2) to calculate the energy expenditure (kJ/min)
Measured as the incremental area under the curve (iAUC) from 0 minutes to 140 minutes after meal intake

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline energy expenditure
Zeitfenster: Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
Energy expenditure will be measured using indirect calorimetry (ventilated hood system). This system measures VO2 and VCO2 to calculate the energy expenditure (kJ/min).
Measured as the incremental area under the curve (iAUC) from 160 minutes to 200 minutes and from 220 minutes to 260 minutes after meal intake
Postprandial lipid and glucose oxidation
Zeitfenster: At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
Lipid and glucose oxidation will be calculated from indirect calorimetry data (VO2 and VCO2).
At baseline (T0, fasting) and between 0 minutes and 140 minutes, between 160 minutes and 200 minutes and between 220 minutes and 260 minutes after meal consumption
Metabolic flexibility
Zeitfenster: At 60, 120, 180 and 240 minutes after meal intake
Metabolic flexibility will be derived from indirect calorimetry as the difference in respiratory quotient (RQ) between fasting and postprandial conditions.
At 60, 120, 180 and 240 minutes after meal intake
Markers for lipid metabolism
Zeitfenster: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
Several markers for lipid metabolism will be measured in blood samples.
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
Markers for glucose metabolism
Zeitfenster: At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
Several markers for glucose metabolism will be measured in blood samples.
At baseline (T0) and at regular intervals up to 240 minutes after meal consumption
Inflammatory status
Zeitfenster: At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption
Several markers for inflammatory status will be measured in blood samples and in vitro conditions
At baseline (T0) and at 60, 120, 180 and 240 minutes after meal consumption

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Maastricht University Medical Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. April 2016

Primärer Abschluss (Tatsächlich)

1. Dezember 2016

Studienabschluss (Tatsächlich)

1. Dezember 2016

Studienanmeldedaten

Zuerst eingereicht

18. April 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. Mai 2016

Zuerst gepostet (Schätzen)

23. Mai 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

1. Februar 2017

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

31. Januar 2017

Zuletzt verifiziert

1. April 2016

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • METC 15-3-060

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Lycium Barbarum mixed meal

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Australia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren